Cognition Therapeutics
Nasdaq CGTX · Purchase, NY
Works in Neurology · Ophthalmology · Psychiatry
Cognition Therapeutics is a clinical trial sponsor based in Purchase, NY, listed as Nasdaq CGTX. It has 1 active clinical trial with 540 planned participants, in Neurology, Ophthalmology and Psychiatry. Since 2021 it has completed 7 trials and stopped 1 early.
Trial track record · since 2021
Financials · Nasdaq CGTX
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about Cognition Therapeutics
Cognition Therapeutics is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 540 planned participants, in Neurology, Ophthalmology, Psychiatry. Since 2021 it has completed 7 trials and stopped 1 early.
Cognition Therapeutics is based in Purchase, NY and is listed as Nasdaq CGTX. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Cognition Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-08-10.
Approve Suite is not affiliated with Cognition Therapeutics.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.